Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer
Description
Dr Liu talks to ecancertv at ASCO 2014 about the findings from a federally funded, NCI-sponsored phase II study which suggest that the combination of two investigational oral drugs, the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib, is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.
At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.
Published 07/15/14
ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.
Published 07/11/14